Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
复制标题
司来吉兰作为帕金森病的主要治疗药物——一项长期双盲研究
DOI：
10.1111/j.1600-0404.1997.tb00101.x
复制
发表时间：
1997
影响因子：
3.5
通讯作者：
E. Heinonen
中科院分区：
文献类型：
--
作者：
V. Myllylä;K. Sotaniemi;P. Hakulinen;O. Mäki‐lkola;E. Heinonen
目的：评价司来吉兰联合左旋多巴长期治疗帕金森病(PD)的疗效。材料和方法：对44例帕金森病患者进行了随机、前瞻性、双盲研究，这些患者在最初的安慰剂或司来吉兰双盲治疗后需要左旋多巴治疗。经联合治疗后随访5年。结果--司格利兰显著降低了(P<；0.001)增加左旋多巴每日剂量以补偿疾病进展的需要。经过5年的联合治疗，司来吉兰组左旋多巴的平均剂量降低了320 mg(405±59 mg比725±78 mg)。两组之间的左旋多巴剂量差异随着随访时间的延长而增加，左旋多巴剂量的比率(安慰剂/司来吉林组)也是如此。司来吉兰组补偿运动波动所需的左旋多巴每日剂量明显较低。帕金森病的残疾在两组之间没有差别，因为通过调整左旋多巴的剂量尽可能地保持了临床状况的最佳。与司来吉兰组的1名患者相比，安慰剂组中有9名患者需要开始额外的多巴胺能治疗(P=0.004)。在5年的随访期内，11名患者退出司来吉林组，其中7名患者因不良事件。两组患者的死亡率没有差异。结论：司来西林治疗帕金森病具有良好的远期疗效。
Introduction – To assess the therapeutic efficacy of selegiline combined with levodopa in the long‐term treatment of Parkinson's disease (PD). Material and methods – A randomized, prospective, double‐blind study on 44 patients with PD needing levodopa therapy after the initial double‐blind treatment with placebo or selegiline was carried out. The patients were followed‐up for 5 years under combination therapy. Results – Selegiline induced a significant (P < 0.001) slowing in the need to increase the daily levodopa dose in order to compensate for the progression of the disease. After 5 years of combination therapy the mean dose of levodopa was on average 320 mg lower in the selegiline group (405 ± 59 mg vs 725 ± 78 mg). The difference in the levodopa doses between the two groups increased along with follow‐up time, as also the ratio of the levodopa doses (placebo/selegiline group). The number of daily levodopa doses needed to compensate for the occurrence of motor fluctuations was significantly lower in the selegiline group. The parkinsonian disability did not differ between the two groups because the clinical condition was kept as optimal as possible by adjusting the levodopa dosage. Nine patients in the placebo group needed initiation of additional dopaminergic therapy in comparison to one in the selegiline group (P=0.004). During the 5‐year follow‐up period 11 patients were withdrawn from the selegiline group, 7 due to adverse events. There was no difference in mortality between the two groups. Conclusion – Selegiline therapy offers beneficial long‐term effects in the treatment of PD.
影响因子：
158.5
作者：
SHOULSON, I;FAHN, S;PELUSIO, RM
通讯作者：
PELUSIO, RM
丙炔苯丙胺对早期帕金森病残疾进展的影响。
DOI：
10.1056/nejm198911163212004
发表时间：
1989
期刊：
The New England journal of medicine
影响因子：
--
作者：
ParkinsonStudyGroup
通讯作者：
ParkinsonStudyGroup
丙炔苯丙胺对 DSP-4 诱导的神经毒性的保护与其对 MAO B 的抑制无关。
影响因子：
5
作者：
Finnegan,KT;Skratt,JJ;Irwin,I;DeLanney,LE;Langston,JW
通讯作者：
Langston,JW